Stock photo. Posed by model.

The VISION Study

A new global phase 3 clinical research study in men with progressive metastatic castration-resistant prostate cancer (mCRPC), called the VISION study, will evaluate the effectiveness and safety of the investigational drug 177Lu-PSMA-617 in combination with the best standard of care versus patients treated with best standard of care alone. This research is being conducted by physicians in approximately 80 institutions throughout the US, Canada, and Europe and will include approximately 750 men who are eligible for the trial.

All men who qualify and choose to participate in the phase 3 clinical study will receive best supportive/best standard-of-care treatment as prescribed by their physician. Two of three patients (67%) also will receive the investigational drug 177Lu-PSMA-617.

To participate in the VISION study, you must be at least 18 years of age and have progressive metastatic castration-resistant prostate cancer that is defined as “PSMA-positive” by an imaging scan - which means your cancer expresses the PSMA protein on its surface. You must have been treated previously with at least 1 previous taxane therapy, and you must have been previously treated with 1 novel androgen-axis therapy. Additional eligibility criteria apply; click here to learn more.

For more study information, and to see if you qualify for participation, talk to your physician.

Click here for a list of questions you may want to ask your physician about participating in a clinical study, and here to learn more about clinical studies in general.

Stock photo. Posed by model.

If you or your doctor are interested in obtaining more information on this research study, please visit, a website service of the United States National Institutes of Health.